Mechanism of cancer drug resistance and the involvement of noncoding RNAs

Current Medicinal Chemistry

Volumn 21, Issue 26, 2014, Pages 3029-3041

  Xia, Hongping ^a   Hui, Kam M ^a,b,c,d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Cancer stem cells; Drug resistance; Epithelial mesenchymal transition (EMT); Long non coding RNAs (lncRNAs); MicroRNA

Indexed keywords

ANTINEOPLASTIC AGENT; LONG UNTRANSLATED RNA; MICRORNA; UNTRANSLATED RNA;

ACQUIRED RESISTANCE; ALTERNATIVE RNA SPLICING; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL CYCLE PARAMETERS; DNA DAMAGE; DNA REPAIR; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; INTRINSIC RESISTANCE; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION;

EID: 84906086776     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140414101939     Document Type: Review

References (190)

1. Ellis, L.M.; Hicklin, D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res., 2009, 15(24), 7471-7478.
2. Vitale, M. Targeted Therapy for Thyroid Cancer: Striking the Survival Signaling. J. Clin. Endocrinol. Metab., 2011, 96(4), 936-938.
3. Barouch-Bentov, R.; Sauer, K. Mechanisms of drug resistance in kinases. Expert. Opin. Investig. Drugs, 2011, 20(2), 153-208.
4. Zahreddine, H.; Borden, K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol., 2013, 4, 28.
5. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010, 29(34), 4741-4751.
6. Galasso, M.; Elena Sana, M.; Volinia, S. Non-coding RNAs: a key to future personalized molecular therapy. Genome. Med., 2010, 2(2), 12.
7. Guttman, M.; Rinn, J.L. Modular regulatory principles of large non-coding RNAs. Nature, 2012, 482(7385), 339-346.
8. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet., 2009, 10(3), 155-159.
9. Kuczynski, E.A.; Sargent, D.J.; Grothey, A.; Kerbel, R.S. Drug rechallenge and treatment beyond progression[mdash]implications for drug resistance. Nat. Rev. Clin. Oncol., 2013, 10(10), 571-587.
10. Vasiliou, V.; Vasiliou, K.; Nebert, D.W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics, 2009, 3(3), 281-290.
11. Breier, A.; Gibalova, L.; Seres, M.; Barancik, M.; Sulova, Z. New Insight into P-glycoprotein as a drug target. Anticancer Agents Med. Chem., 2013, 13(1), 159-170.
12. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U S A., 1987, 84(21), 7735-7738.
13. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53(1), 615-627.
14. Trock, B.J.; Leonessa, F.; Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst., 1997, 89(13), 917-931.
15. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins. J. Natl. Cancer Inst., 2000, 92(16), 1295-1302.
16. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
17. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res., 2001, 42(7), 1007-1017.
18. Akhdar, H.; Legendre, C.; Aninat, C.; More, F. Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches. in: Topics on Drug Metabolism, James Paxton, Ed.; InTech., 2012, pp. 137-170.
19. Guengerich, F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol., 2007, 21(1), 70-83.
20. Sim, S.C.; Ingelman-Sundberg, M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum. Genomics, 2010, 4(4), 278-281.
21. Basseville, A.; Preisser, L.; de Carné Trécesson, S.; Boisdron-Celle, M.; Gamelin, E.; Coqueret, O.; Morel, A. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol. Cancer, 2011, 10, 80.
22. Pondugula, S.R.; Mani, S. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett., 2013, 328(1), 1-9.
23. Chen, J.; Raymond, K. Nuclear receptors, bile-acid detoxification, and cholestasis. Lancet, 2006, 367(9509), 454-456.
24. Chen, Y.; Tang, Y.; Guo, C.; Wang, J.; Boral, D.; Nie, D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol., 2012, 83(8), 1112-1126.
25. Ziglari, T.; Allameh, A. The Significance of Glutathione Conjugation in Aflatoxin Metabolism. in: Aflatoxins-Recent Advances and Future Prospects,Mehdi Razzaghi-Abyaneh, Ed,; InTech, 2013, pp.267-286.
26. Kumar, R.; Chaudhary, K.; Gupta, S.; Singh, H.; Kumar, S.; Gautam, A.; Kapoor, P.; Raghava, G.P.S. CancerDR: Cancer Drug Resistance Database. Sci. Rep., 2013, 3, 1445.
27. Henkes, M.; van der Kuip, H.; Aulitzky, W.E. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec® , Gleevec™). Ther. Clin. Risk Manag., 2008, 4(1), 163-187.
28. Nahta, R.; Yu, D.; Hung, M.-C.; Hortobagyi, G.N.; Esteva, F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol., 2006, 3(5), 269-280.
29. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch Jr, T.J.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA, 2003, 290(16), 2149-2158.
30. Ou, S.-H.I. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des. Devel. Ther., 2011, 5, 471-485.
31. Flaherty, K.T.; Yasothan, U.; Kirkpatrick, P. Vemurafenib. Nat. Rev. Drug Discov., 2011, 10(11), 811-812.
32. Gambacorti-Passerini, C.B.; Gunby, R.H.; Piazza, R.; Galietta, A.; Rostagno, R.; Scapozza, L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol., 2003, 4(2), 75-85.
33. Nahta, R.; Esteva, F.J. Molecular mechanisms of trastuzumab resistance. Breast Cancer Res., 2006, 8(6), 667-674.
34. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2(3), e73.
35. Kim, S.; Kim, T.M.; Kim, D.-W.; Go, H.; Keam, B.; Lee, S.-H.; Ku, J.-L.; Chung, D.H.; Heo, D.S. Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALKRearranged Lung Cancer. J. Thorac. Oncol., 2013, 8(4), 415-422.
36. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R.C.; Lee, H.; Chen, Z.; Lee, M.-K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S.F.; McArthur, G.; Sosman, J.A.; Ribas, A.; Lo, R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468(7326), 973-977.
37. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; Cooper, Z.A.; Chapman, P.B.; Solit, D.B.; Ribas, A.; Lo, R.S.; Flaherty, K.T.; Ogino, S.; Wargo, J.A.; Golub, T.R. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487(7408), 500-504.
38. Wilson, T.R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D.P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487(7408), 505-509.
39. Thakur, M.D.; Salangsang, F.; Landman, A.S.; Sellers, W.R.; Pryer, N.K.; Levesque, M.P.; Dummer, R.; McMahon, M.; Stuart, D.D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 2013, 494(7436), 251-255.
40. Salehan, M.; Morse, H. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br. J. Biomed. Sci., 2013, 70(1), 31-40.
41. Shah, M.A.; Schwartz, G.K. Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy. Clin. Cancer Res., 2001, 7(8), 2168-2181.
42. Schwartz, G.K.; Shah, M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol., 2005, 23(36), 9408-9421.
43. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 2003, 94(1), 15-21.
44. Okada, H.; Mak, T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer, 2004, 4(8), 592-603.
45. Marquez, R.T.; Tsao, B.W.; Faust, N.F.; Xu, L. Drug Resistance and Molecular Cancer Therapy: Apoptosis Versus Autophagy. in: Apoptosis, Justine Rudner, Ed.; InTech, 2013, pp.155-196.
46. Mathew, R.; Karantza-Wadsworth, V.; White, E. Role of autophagy in cancer. Nat. Rev. Cancer, 2007, 7(12), 961-967.
47. Han, W.; Pan, H.; Chen, Y.; Sun, J.; Wang, Y.; Li, J.; Ge, W.; Feng, L.; Lin, X.; Wang, X. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS ONE, 2011, 6(6), e18691.
48. Swampillai, A.; Salomoni, P.; Short, S. The role of autophagy in clinical practice. Clin. Oncol., 2012, 24(6), 387-395.
49. Zavadil, J.; Haley, J.; Kalluri, R.; Muthuswamy, S.K.; Thompson, E. Epithelial-Mesenchymal Transition. Cancer Res., 2008, 68(23), 9574-9577.
50. Xia, H.; Hui, K.M. MicroRNAs involved in regulating epithelialmesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther., 2012, 19(11), 723-730.
51. Welte, Y.; Adjaye, J.; Lehrach, H.R.; Regenbrecht, C.R. Cancer stem cells in solid tumors: elusive or illusive? Cell. Commun. Signal., 2010, 8(1), 6.
52. Ouyang, G. Epithelial-Mesenchymal Transition and Cancer Stem Cells. in: Cancer Stem Cells-The Cutting Edge, Stanley Shostak, Ed., InTech, 2011, pp.167-188.
53. Uramoto, H.; Iwata, T.; Onitsuka, T.; Shimokawa, H.; Hanagiri, T.; Oyama, T. Epithelial- Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma. Anticancer Res., 2010, 30(7), 2513-2517.
54. Pao, W.; Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer, 2010, 10(11), 760-774.
55. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir., 2009, 64(5), 489-500.
56. Sui, H.; Fan, Z.; Li, Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J. Int. Med. Res., 2012, 40(2), 426-435.
57. Yan, F.; Wang, X.-M.; Liu, Z.-C.; Pan, C.; Yuan, S.-B.; Ma, Q.-M. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat. Dis. Int., 2010, 9(3), 287-295.
58. O'Brian, C.A.; Ward, N.E.; Stewart, J.R.; Chu, F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer-an evolving story. Cancer Metastasis Rev., 2001, 20(1-2), 95-100.
59. Fenouille, N.; Puissant, A.; Dufies, M.; Robert, G.; Jacquel, A.; Ohanna, M.; Deckert, M.; Pasquet, J.-M.; Mahon, F.-X.; Cassuto, J.-P. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res., 2010, 70(23), 9659-9670.
60. Pohlmann, P.R.; Mayer, I.A.; Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res., 2009, 15(24), 7479-7491.
61. Zhang, Z.; Lee, J.C.; Lin, L.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A.D.; Rho, J.K.; Choi, Y.J.; Choi, C.-M.; Kim, S.-W.; Jang, S.J.; Park, Y.S.; Kim, W.S.; Lee, D.H.; Lee, J.-S.; Miller, V.A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T.J.; Ma, P.C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T.G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet., 2012, 44(8), 852-860.
62. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Jänne, P.A. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 316(5827), 1039-1043.
63. Sasaki, T.; Koivunen, J.; Ogino, A.; Yanagita, M.; Nikiforow, S.; Zheng, W.; Lathan, C.; Marcoux, J.P.; Du, J.; Okuda, K. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res., 2011, 71(18), 6051-6060.
64. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer, 2012, 12(12), 801-817.
65. Talbot, L.J.; Bhattacharya, S.D.; Kuo, P.C. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int. J. Biochem. Mol. Biol., 2012, 3(2), 117-136.
66. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A.S.; Ali, S.; Abbruzzese, J.L.; Gallick, G.E.; Sarkar, F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res., 2009, 69(6), 2400-2407.
67. Li, J.; Zhou, B.P. Activation of -catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer, 2011, 11, 49.
68. Cooper, T.A.; Wan, L.; Dreyfuss, G. RNA and disease. Cell, 2009, 136(4), 777-793.
69. Marchelli, R.; Corradini, R.; Manicardi, A.; Sforza, S.; Tedeschi, T.; Fabbri, E.; Borgatti, M.; Bianchi, N.; Gambari, R. Gene modulation by peptide nucleic acids (PNAs) targeting microRNAs (miRs). in: Targets in Gene Therapy, Yongping You, Ed.; InTech., 2011.
70. Ha, T.-Y. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw., 2011, 11(3), 135-154.
71. Zhu, H.; Wu, H.; Liu, X.; Evans, B.R.; Medina, D.J.; Liu, C.-G.; Yang, J.-M. Role of MicroRNA miR-27a and miR-451 in the regulation of i MDR/i 1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol., 2008, 76(5), 582-588.
72. Kovalchuk, O.; Filkowski, J.; Meservy, J.; Ilnytskyy, Y.; Tryndyak, V.P.; Vasyl'F, C.; Pogribny, I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther., 2008, 7(7), 2152-2159.
73. Zhao, X.; Yang, L.; Hu, J.; Ruan, J. miR-138 might reverse multidrug resistance of leukemia cells. Leuk. Res., 2010, 34(8), 1078-1082.
74. Bao, L.; Hazari, S.; Mehra, S.; Kaushal, D.; Moroz, K.; Dash, S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol., 2012, 180(6), 2490-2503.
75. Ikemura, K.; Yamamoto, M.; Miyazaki, S.; Mizutani, H.; Iwamoto, T.; Okuda, M. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol. Pharmacol., 2013, 83(2), 399-405.
76. Wang, F.; Li, T.; Zhang, B.; Li, H.; Wu, Q.; Yang, L.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem. Biophys. Res. Commun., 2013, 434(3), 688-694.
77. Boyerinas, B.; Park, S.M.; Murmann, A.E.; Gwin, K.; Montag, A.G.; Zillhardt, M.; Hua, Y.J.; Lengyel, E.; Peter, M.E. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int. J. Cancer, 2012, 130(8), 1787-1797.
78. Li, X.; Pan, Y.-Z.; Seigel, G.M.; Hu, Z.-H.; Huang, M.; Yu, A.-M. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328,-519c and-520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol., 2011, 81(6), 783-792.
79. San José-Enériz, E.; Roma´n-Gómez, J.; Jiménez-Velasco, A.; Garate, L.; Martin, V.; Cordeu, L.; Vilas-Zornoza, A.; Rodríguez-Otero, P.; Calasanz, M.J.; Prósper, F. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol. Cancer, 2009, 8, 69.
80. Lopotová, T.; -á-ková, M.; Klamová, H.; Moravcová, J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk. Res., 2011, 35(7), 974-977.
81. Yu, Y.; Yang, L.; Zhao, M.; Zhu, S.; Kang, R.; Vernon, P.; Tang, D.; Cao, L. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia, 2012, 26(8), 1752-1760.
82. Faber, J.; Gregory, R.I.; Armstrong, S.A. Linking miRNA regulation to BCR-ABL expression: The next dimension. Cancer Cell, 2008, 13(6), 467-469.
83. Bueno, M.J.; Pérez de Castro, I.; Gómez de Cedrón, M.; Santos, J.; Calin, G.A.; Cigudosa, J.C.; Croce, C.M.; Fernández- Piqueras, J.; Malumbres, M. Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer Cell, 2008, 13(6), 496-506.
84. Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem., 2011, 286(21), 19127-19137.
85. Jung, E.J.; Santarpia, L.; Kim, J.; Esteva, F.J.; Moretti, E.; Buzdar, A.U.; Di Leo, A.; Le, X.F.; Bast, R.C.; Park, S.T. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118(10), 2603-2614.
86. Ichikawa, T.; Sato, F.; Terasawa, K.; Tsuchiya, S.; Toi, M.; Tsujimoto, G.; Shimizu, K. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS ONE, 2012, 7(2), e31422.
87. Wang, Y.-S.; Wang, Y.-H.; Xia, H.-P.; Zhou, S.-W.; Schmid-Bindert, G.; Zhou, C.-C. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFRmutant cell lines. Asian Pac. J. Cancer Prev., 2012, 13(1), 255-260.
88. Garofalo, M.; Romano, G.; Di Leva, G.; Nuovo, G.; Jeon, Y.-J.; Ngankeu, A.; Sun, J.; Lovat, F.; Alder, H.; Condorelli, G. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med., 2011, 18(1), 74-82.
89. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet., 2011, 12(12), 861-874.
90. Amaral, P.P.; Clark, M.B.; Gascoigne, D.K.; Dinger, M.E.; Mattick, J.S. lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res., 2011, 39(suppl 1), D146-D151.
91. Consortium, T.E.P. An integrated encyclopedia of DNA elements in the human genome. Nature, 2012, 489(7414), 57-74.
92. Im, J.H.; Muschel, R.J. New evidence of lncRNA role in tumor progression and metastasis. Hepatobiliary Surg. Nutr., 2012, 1(1), 55-56.
93. Fu, X.; Ravindranath, L.; Tran, N.; Petrovics, G.; Srivastava, S. Regulation of apoptosis by a prostate-specific and prostate cancerassociated noncoding gene, PCGEM1. DNA Cell Biol., 2006, 25(3), 135-141.
94. Nie, L.; Wu, H.-J.; Hsu, J.-M.; Chang, S.-S.; LaBaff, A.M.; Li, C.-W.; Wang, Y.; Hsu, J.L.; Hung, M.-C. Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am. J. Transl. Res., 2012, 4(2), 127-150.
95. Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T.S. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene, 2007, 26(6), 851-858.
96. Godinho, M.; Sieuwerts, A.; Look, M.; Meijer, D.; Foekens, J.; Dorssers, L.; van Agthoven, T. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br. J. Cancer, 2010, 103(8), 1284-1291.
97. Doyle, L.A.; Yang, W.; Rishi, A.K.; Gao, Y.; Ross, D.D. H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res., 1996, 56(13), 2904-2907.
98. Tsang, W.P.; Kwok, T. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene, 2007, 26(33), 4877-4881.
99. Tiemann, K.; Rossi, J.J. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med., 2009, 1(3), 142-151.
100. Kassam, F.; Enright, K.; Dent, R.; Dranitsaris, G.; Myers, J.; Flynn, C.; Fralick, M.; Kumar, R.; Clemons, M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer, 2009, 9(1), 29-33.
101. van Rooij, E.; Purcell, A.L.; Levin, A.A. Developing MicroRNA Therapeutics. Circ. Res., 2012, 110(3), 496-507.
102. Bader, A.G.; Brown, D.; Winkler, M. The promise of microRNA replacement therapy. Cancer Res., 2010, 70(18), 7027-7030.
103. Hong, L.; Han, Y.; Zhang, Y.; Zhang, H.; Zhao, Q.; Wu, K.; Fan, D. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin. Ther. Targets, 2013, 17(9), 1073-1080.
104. Yang, F.; Li, Q.; Gong, Z.; Zhou, L.; You, N.; Wang, S.; Li, X.; Li, J.; An, J.; Wang, D. MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment. Technol. Cancer Res. Treat., 2014, 13(1), 77-86.
105. Qiu, T.; Zhou, L.; Wang, T.; Xu, J.; Wang, J.; Chen, W.; Zhou, X.; Huang, Z.; Zhu, W.; Shu, Y. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int. J. Mol. Med., 2013, 32(3), 593-598.
106. Sugimura, K.; Miyata, H.; Tanaka, K.; Hamano, R.; Takahashi, T.; Kurokawa, Y.; Yamasaki, M.; Nakajima, K.; Takiguchi, S.; Mori, M.; Doki, Y. Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res., 2012, 18(18), 5144-5153.
107. Bhutia, Y.D.; Hung, S.W.; Krentz, M.; Patel, D.; Lovin, D.; Manoharan, R.; Thomson, J.M.; Govindarajan, R. Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein. PLoS ONE, 2013, 8(1), e53436.
108. Zhao, Y.; Deng, C.; Lu, W.; Xiao, J.; Ma, D.; Guo, M.; Recker, R.R.; Gatalica, Z.; Wang, Z.; Xiao, G.G. Let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor - signaling in breast cancer. Mol. Med., 2011, 17(11-12), 1233-1241.
109. Masuda, M.; Miki, Y.; Hata, S.; Takagi, K.; Sakurai, M.; Ono, K.; Suzuki, K.; Yang, Y.; Abe, E.; Hirakawa, H. An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J. Transl. Med., 2012, 10(Suppl 1), S2.
110. Nishida, N.; Yamashita, S.; Masaki Mori, M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann. Surg. Oncol., 2012, 19(9), 3065-3071.
111. Rao, E.; Jiang, C.; Ji, M.; Huang, X.; Iqbal, J.; Lenz, G.; Wright, G.; Staudt, L.M.; Zhao, Y.; McKeithan, T.W.; Chan, W.C.; Fu, K. The miRNA-17[sim]92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia, 2012, 26(5), 1064-1072.
112. Kurokawa, K.; Tanahashi, T.; Iima, T.; Yamamoto, Y.; Akaike, Y.; Nishida, K.; Masuda, K.; Kuwano, Y.; Murakami, Y.; Fukushima, M. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J. Gastroenterol., 2012, 47(8), 883-895.
113. Wang, F.; Li, T.; Zhang, B.; Li, H.; Wu, Q.; Yang, L.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem. Biophys. Res. Commun., 2013, 434(3), 688-694.
114. Wong, S.T.S.; Zhang, X.-Q.; Zhuang, J.T.-F.; Chan, H.-L.; Li, C.-H.; Leung, G.K.K. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res., 2012, 32(7), 2835-2841.
115. Yang, S.-m.; Huang, C.; Li, X.-f.; Yu, M.-z.; He, Y.; Li, J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology, 2013, 306, 162-168.
116. PAIK, W.H.; KIM, H.R.; PARK, J.K.; SONG, B.J.; LEE, S.H.; HWANG, J.-H. Chemosensitivity Induced by Down-regulation of MicroRNA-21 in Gemcitabine-resistant Pancreatic Cancer Cells by Indole-3-Carbinol. Anticancer Res., 2013, 33(4), 1473-1481.
117. Liu, Z.-L.; Wang, H.; Liu, J.; Wang, Z.-X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell Biochem., 2013, 372(1-2), 35-45.
118. Li, J.; Zhang, Y.; Zhao, J.; Kong, F.; Chen, Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol. Cell. Biochem., 2011, 357(1-2), 31-38.
119. Zhang, J.-X.; Qian, D.; Wang, F.-W.; Liao, D.-Z.; Wei, J.-H.; Tong, Z.-T.; Fu, J.; Huang, X.-X.; Liao, Y.-J.; Deng, H.-X. MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett., 2013, 329(1), 91-98.
120. Yu, Y.; Cao, L.; Yang, L.; Kang, R.; Lotze, M.; Tang, D. microRNA 30A promotes autophagy in response to cancer therapy. Autophagy, 2012, 8(5), 853-855.
121. Zou, Z.; Wu, L.; Ding, H.; Wang, Y.; Zhang, Y.; Chen, X.; Chen, X.; Zhang, C.-Y.; Zhang, Q.; Zen, K. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J. Biol. Chem., 2012, 287(6), 4148-4156.
122. Bockhorn, J.; Dalton, R.; Nwachukwu, C.; Huang, S.; Prat, A.; Yee, K.; Chang, Y.-F.; Huo, D.; Wen, Y.; Swanson, K.E. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat. Commun., 2013, 4, 1393.
123. Catuogno, S.; Cerchia, L.; Romano, G.; Pognonec, P.; Condorelli, G.; de Franciscis, V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene, 2013, 32(3), 341-351.
124. Körner, C.; Keklikoglou, I.; Bender, C.; Wörner, A.; Münstermann, E.; Wiemann, S. MicroRNA-31 Sensitizes Human Breast Cells to Apoptosis by Direct Targeting of Protein Kinase C - (PKC-). J. Biol. Chem., 2013, 288(12), 8750-8761.
125. Li, X.-j.; Ji, M.-h.; Zhong, S.-l.; Zha, Q.-b.; Xu, J.-j.; Zhao, J.-h.; Tang, J.-h. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch. Med. Res., 2012, 43(7), 514-521.
126. Wu, H.; Huang, M.; Lu, M.; Zhu, W.; Shu, Y.; Cao, P.; Liu, P. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother. Pharmacol., 2013, 71(5), 1159-1171.
127. Fu, X.; Tian, J.; Zhang, L.; Chen, Y.; Hao, Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett., 2012, 586(9), 1279-1286.
128. Wang, Y.; Huang, J.-W.; Calses, P.; Kemp, C.J.; Taniguchi, T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res., 2012, 72(16), 4037-4046.
129. Xiang, Q.; Tang, H.; Yu, J.; Yin, J.; Yang, X.; Lei, X. MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie, 2013, 68(4), 274-281.
130. Feng, B.; Wang, R.; Chen, L.-B. MiR-100 resensitizes docetaxelresistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett., 2012, 317(2), 184-191.
131. Yin, J.; Tang, H.F.; Xiang, Q.; Yu, J.; Yang, X.Y.; Hu, N.; Lei, X.Y. MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. Pharmazie, 2011, 66(12), 975-981.
132. Xu, Y.; Xia, F.; Ma, L.; Shan, J.; Shen, J.; Yang, Z.; Liu, J.; Cui, Y.; Bian, X.; Bie, P. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett., 2011, 310(2), 160-169.
133. Iida, K.; Fukushi, J.-i.; Matsumoto, Y.; Oda, Y.; Takahashi, Y.; Fujiwara, T.; Fujiwara-Okada, Y.; Hatano, M.; Nabashima, A.; Kamura, S. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int., 2013, 13(1), 21.
134. Liu, Z.; Liu, H.; Desai, S.; Schmitt, D.C.; Zhou, M.; Khong, H.T.; Klos, K.S.; McClellan, S.; Fodstad, O.; Tan, M. miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance. J. Biol. Chem., 2013, 288(6), 4334-4345.
135. Zhang, H.; Luo, X.-Q.; Feng, D.-D.; Zhang, X.-J.; Wu, J.; Zheng, Y.-S.; Chen, X.; Xu, L.; Chen, Y.-Q. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol. Cancer, 2011, 10, 108.
136. Shi, L.; Zhang, S.; Feng, K.; Wu, F.; Wan, Y.; Wang, Z.; Zhang, J.; Wang, Y.; Yan, W.; Fu, Z. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int. J. Oncol., 2012, 40(1), 119-129.
137. Zhu, X.; Li, H.; Long, L.; Hui, L.; Chen, H.; Wang, X.; Shen, H.; Xu, W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim. Biophys. Sin., 2012, 44(6), 519-526.
138. Zhu, Y.; Yu, F.; Jiao, Y.; Feng, J.; Tang, W.; Yao, H.; Gong, C.; Chen, J.; Su, F.; Zhang, Y. Reduced miR-128 in breast tumor- initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res., 2011, 17(22), 7105-7115.
139. Yang, C.; Cai, J.; Wang, Q.; Tang, H.; Cao, J.; Wu, L.; Wang, Z. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colonystimulating factor 1. Gynecol. Oncol., 2012, 124(2), 325-334.
140. Zhou, L.; Qiu, T.; Xu, J.; Wang, T.; Wang, J.; Zhou, X.; Huang, Z.; Zhu, W.; Shu, Y.; Liu, P. miR-135a/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1. Pathol. Oncol. Res., 2013, 19(4), 677-683.
141. Holleman, A.; Chung, I.; Olsen, R.R.; Kwak, B.; Mizokami, A.; Saijo, N.; Parissenti, A.; Duan, Z.; Voest, E.E.; Zetter, B.R. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene, 2011, 30(43), 4386-4398.
142. Imanaka, Y.; Tsuchiya, S.; Sato, F.; Shimada, Y.; Shimizu, K.; Tsujimoto, G. MicroRNA-141 confers resistance to cisplatininduced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J. Hum. Genet., 2011, 56(4), 270-276.
143. van Jaarsveld, M.; Helleman, J.; Boersma, A.; van Kuijk, P.; van Ijcken, W.; Despierre, E.; Vergote, I.; Mathijssen, R.; Berns, E.; Verweij, J. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene, 2013, 32(36), 4284-4293.
144. Qian, X.; Yu, J.; Yin, Y.; He, J.; Wang, L.; Li, Q.; Zhang, L.-Q.; Li, C.-Y.; Shi, Z.-M.; Xu, Q. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle, 2013, 12(9), 1385-1394.
145. Xu, B.; Niu, X.; Zhang, X.; Tao, J.; Wu, D.; Wang, Z.; Li, P.; Zhang, W.; Wu, H.; Feng, N. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol. Cell Biochem., 2011, 350(1-2), 207-213.
146. Tomokuni, A.; Eguchi, H.; Tomimaru, Y.; Wada, H.; Kawamoto, K.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Nagano, H.; Mori, M. miR-146a suppresses the sensitivity to interferon- in hepatocellular carcinoma cells. Biochem. Bioph. Res. Commun., 2011, 414(4), 675-680.
147. Delpu, Y.; Lulka, H.; Sicard, F.; Saint-Laurent, N.; Lopez, F.; Hanoun, N.; Buscail, L.; Cordelier, P.; Torrisani, J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS ONE,2013, 8(1), e55513.
148. Hummel, R.; Watson, D.I.; Smith, C.; Kist, J.; Michael, M.Z.; Haier, J.; Hussey, D.J. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J. Gastrointest. Surg., 2011, 15(3), 429-438.
149. Liu, L.; Chen, R.; Huang, S.; Wu, Y.; Li, G.; Zhang, B.; Liu, Q.; Yin, D.; Liang, Y. miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med. Oncol., 2012, 29(1), 243-247.
150. Zang, Y.; Zhong, Y.; Fang, Z.; Li, B.; An, J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther., 2012, 19(11), 773-778.
151. Jiao, X.; Zhao, L.; Ma, M.; Bai, X.; He, M.; Yan, Y.; Wang, Y.; Chen, Q.; Zhao, X.; Zhou, M. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res. Treat., 2013, 139(3), 717-730.
152. Li, H.; Hui, L.; Xu, W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta. Biochim. Biophys. Sin., 2012, 44(3), 269-277.
153. Bai, H.; Cao, Z.; Deng, C.; Zhou, L.; Wang, C. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J. Cancer Res. Clin. Oncol., 2012, 138(4), 595-602.
154. Yang, A.; Ma, J.; Wu, M.; Qin, W.; Zhao, B.; Shi, Y.; Jin, Y.; Xie, Y. Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk. Lymphoma, 2012, 53(12), 2465-2473.
155. Moskwa, P.; Buffa, F.M.; Pan, Y.; Panchakshari, R.; Gottipati, P.; Muschel, R.J.; Beech, J.; Kulshrestha, R.; Abdelmohsen, K.; Weinstock, D.M. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell., 2011, 41(2), 210-220.
156. Qu, J.; Zhao, L.; Zhang, P.; Wang, J.; Xu, N.; Mi, W.; Jiang, X.; Zhang, C. MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J. Cell Physiol., 2013 doi: 10.1002/jcp.24366. [Epub ahead of print]
157. Yang, X.; Yin, J.; Yu, J.; Xiang, Q.; Liu, Y.; Tang, S.; Liao, D.; Zhu, B.; Zu, X.; Tang, H. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol. Rep., 2012, 27(1), 250-257.
158. Xu, N.; Zhang, J.; Shen, C.; Luo, Y.; Xia, L.; Xue, F.; Xia, Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun., 2012, 423(4), 826-831.
159. Shatseva, T.; Lee, D.Y.; Deng, Z.; Yang, B.B. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J. Cell Sci., 2011, 124(16), 2826-2836.
160. Chen, R.; Alvero, A.B.; Silasi, D.A.; Kelly, M.G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P.E.; Rutherford, T.; Mor, G. Regulation of IKK[beta] by miR-199a affects NF-[kappa]B activity in ovarian cancer cells. Oncogene, 2008, 27(34), 4712-4723.
161. Feng, B.; Wang, R.; Song, H.Z.; Chen, L.B. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer, 2012, 118(13), 3365-3376.
162. Liu, S.; Tetzlaff, M.T.; Cui, R.; Xu, X. miR-200c inhibits melanoma progression and drug resistance through downregulation of Bmi-1. Am. J. Pathol., 2012, 181(5), 1823-1835.
163. Kopp, F.; Oak, P.S.; Wagner, E.; Roidl, A. miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression. PLoS ONE, 2012, 7(11), e50469.
164. Hamano, R.; Miyata, H.; Yamasaki, M.; Kurokawa, Y.; Hara, J.; ho Moon, J.; Nakajima, K.; Takiguchi, S.; Fujiwara, Y.; Mori, M. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin. Cancer Res., 2011, 17(9), 3029-3038.
165. Chang, L.; Guo, F.; Wang, Y.; Lv, Y.; Huo, B.; Wang, L.; Liu, W. MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE. Pathol. Oncol. Res., 2014, 20(1), 93-98.
166. Zhu, W.; Xu, H.; Zhu, D.; Zhi, H.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother. Pharmacol., 2012, 69(3), 723-731.
167. Li, J.; Chen, Y.; Zhao, J.; Kong, F.; Zhang, Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett., 2011, 304(1), 52-59.
168. Ru, P.; Steele, R.; Hsueh, E.C.; Ray, R.B. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer, 2011, 2(7), 720-727.
169. Ryan, J.; Tivnan, A.; Fay, J.; Bryan, K.; Meehan, M.; Creevey, L.; Lynch, J.; Bray, I.; O'Meara, A.; Davidoff, A. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br. J. Cancer, 2012, 107(6), 967-976.
170. Wang, F.; Liu, M.; Li, X.; Tang, H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett., 2013, 587(5), 488-495.
171. Xia, H.; Ooi, L.L.P.J.; Hui, K.M. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology, 2013, 58(2), 629-641.
172. Zhao, G.; Cai, C.; Yang, T.; Qiu, X.; Liao, B.; Li, W.; Ji, Z.; Zhao, J.; Zhao, H.; Guo, M.; Ma, Q.; Xiao, C.; Fan, Q.; Ma, B. MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma. PLoS ONE, 2013, 8(1), e53906.
173. Xu, K.; Liang, X.; Shen, K.; Sun, L.; Cui, D.; Zhao, Y.; Tian, J.; Ni, L.; Liu, J. MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp. Cell Res., 2012, 318(17), 2168-2177.
174. Bai, Y.; Liao, H.; Liu, T.; Zeng, X.; Xiao, F.; Luo, L.; Guo, H.; Guo, L. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-A-go-go (EAG1). Eur. J. Cancer, 2013, 49(3), 710-724.
175. Ke, X.; Xin, L.; Ke, S.; Daling, C.; Yuanhong, Z.; Jianhua, X.; Zhongze, F.; Yanyan, Q.; Qi, L.; Lei, N. miR-297 modulates multidrug resistance in human colorectal carcinoma by downregulating MRP-2. Biochem. J., 2012, 446(2), 291-300.
176. Xu, X.T.; Xu, Q.; Tong, J.L.; Zhu, M.M.; Nie, F.; Chen, X.; Xiao, S.; Ran, Z. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br. J. Cancer, 2012, 106(7), 1320-1330.
177. Du, L.; Subauste, M.C.; DeSevo, C.; Zhao, Z.; Baker, M.; Borkowski, R.; Schageman, J.J.; Greer, R.; Yang, C.-R.; Suraokar, M. miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers. PLoS ONE, 2012, 7(6), e39167.
178. Ward, A.; Balwierz, A.; Zhang, J.; Küblbeck, M.; Pawitan, Y.; Hielscher, T.; Wiemann, S.; Sahin, Ö. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 2013, 32(9), 1173-1182.
179. Ye, G.; Fu, G.; Cui, S.; Zhao, S.; Bernaudo, S.; Bai, Y.; Ding, Y.; Zhang, Y.; Yang, B.B.; Peng, C. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J. Cell Sci., 2011, 124(3), 359-368.
180. Bitarte, N.; Bandres, E.; Boni, V.; Zarate, R.; Rodriguez, J.; Gonzalez-Huarriz, M.; Lopez, I.; Javier Sola, J.; Alonso, M.M.; Fortes, P. MicroRNA-451 Is Involved in the Self-renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells. Stem Cells, 2011, 29(11), 1661-1671.
181. Bian, H.-B.; Pan, X.; Yang, J.-S.; Wang, Z.-X.; De, W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res., 2011, 30, 20.
182. Chen, C.-F.; He, X.; Arslan, A.D.; Mo, Y.-Y.; Reinhold, W.C.; Pommier, Y.; Beck, W.T. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase II- and drug responsiveness. Mol. Pharmacol., 2011, 79(4), 735-741.
183. Ma, M.-T.; He, M.; Wang, Y.; Jiao, X.-Y.; Zhao, L.; Bai, X.-F.; Yu, Z.-J.; Wu, H.-Z.; Sun, M.-L.; Song, Z.-G. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett., 2013, 339(1), 107-115.
184. Guo, S.; Jiang, C.; Wang, G.; Li, Y.; Wang, C.; Guo, X.; Yang, R.; Feng, Y.; Wang, F.; Tseng, H. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene, 2013, 32(15), 1910-1920.
185. Zhu, W.; Zhu, D.; Lu, S.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med. Oncol., 2012, 29(1), 384-391.
186. Tong, J.L.; Zhang, C.P.; Nie, F.; Xu, X.T.; Zhu, M.M.; Xiao, S.D.; Ran, Z.H. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin- resistant human colon cancer cells. FEBS Lett., 2011, 585(22), 3560-3568.
187. Zhang, X.; Zhu, J.; Xing, R.; Tie, Y.; Fu, H.; Zheng, X.; Yu, B. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer, 2012, 77(3), 488-494.
188. Hu, H.; Li, S.; Cui, X.; Lv, X.; Jiao, Y.; Yu, F.; Yao, H.; Song, E.; Chen, Y.; Wang, M. The Overexpression of Hypomethylated miR-663 Induces Chemotherapy Resistance in Human Breast Cancer Cells by Targeting Heparin Sulfate Proteoglycan 2 (HSPG2). J. Biol. Chem., 2013, 288(16), 10973-10985.
189. Xu, K.; Liang, X.; Cui, D.; Wu, Y.; Shi, W.; Liu, J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol. Carcinog., 2013, 52(1), 70-78.
190. Yang, Y.; Li, H.; Hou, S.; Hu, B.; Liu, J.; Wang, J. The Noncoding RNA Expression Profile and the Effect of lncRNA AK126698 on Cisplatin Resistance in Non-Small-Cell Lung Cancer Cell. PLoS ONE, 2013, 8(5), e65309.